Stryker Corporation

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

🏛️ Stryker (NYSE: SYK) has officially completed its acquisition of privately held Amplitude Vascular Systems (AVS).

🌐 The deal brings next-generation intravascular lithotripsy (IVL) technology to Stryker's peripheral vascular portfolio.

💡 AVS utilizes innovative CO₂-generated pressure wave technology designed to treat complex peripheral arterial disease.

📍 AVS is a Boston-based medical device company founded in 2017 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D.

💼 Key investors backing AVS include BioStar Capital and Cue Growth Partners.

🗣️ Stryker CEO Kevin Lobo stated the acquisition is a significant milestone for expanding their peripheral vascular capabilities.

🎯 The integration aims to combine AVS's technology with Stryker's global scale and resources to improve patient outcomes.

⚕️ Stryker impacts more than 150 million patients annually across MedSurg, Neurotechnology, and Orthopaedics.

💰 On May 7, 2026, Stryker also declared a quarterly dividend of $0.88 per share.

📉 Analyst Truist lowered its price target for Stryker to $330 from $380 prior to the acquisition news.

📉 Barclays simultaneously lowered its price target for Stryker to $394 from $469 around the same period.

🔄 The company faces conflicting analyst sentiments regarding its healthcare performance in early May 2026.

Bullish Signals
  • Stryker has successfully completed the acquisition of Amplitude Vascular Systems to add next-generation intravascular lithotripsy (IVL) technology to its peripheral vascular portfolio.
  • The deal integrates AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources to deliver solutions that support physicians and patient outcomes.
  • This acquisition is described as a significant milestone in expanding Stryker's peripheral vascular portfolio and enhancing its ability to address challenging arterial disease.
  • Stryker remains a global leader impacting more than 150 million patients annually across MedSurg, Neurotechnology, and Orthopaedics segments.
  • The company declared a quarterly dividend of $0.88 per share on May 7, 2026, returning value to shareholders.
Risk Factors
  • Stryker faces a lowered price target from Truist, which reduced its valuation guidance from $380 to $330 just days after completing the acquisition.
  • Barlarys also downgraded Stryker's stock price target significantly from $469 to $394, indicating analyst concern over recent developments or valuations.
  • Despite the acquisition being described as a 'significant milestone,' conflicting sentiments from investors and analysts suggest mixed confidence in Stryker's immediate future performance.
Full Analysis
Stryker has officially completed its acquisition of Amplitude Vascular Systems, a privately held medical technology firm based in Boston that specializes in treating severely calcified arterial disease. This deal marks a significant strategic milestone for Stryker as it seeks to expand its peripheral vascular portfolio with next-generation intravascular lithotripsy (IVL) technology. The acquired company's core innovation utilizes carbon dioxide-generated pressure waves to effectively treat complex peripheral arterial disease, allowing physicians to manage challenging calcified lesions more efficiently. Kevin Lobo, Chair and CEO of Stryker, emphasized that integrating Amplitude Vascular Systems' CO₂-based technology with Stryker's extensive resources will enhance the company's ability to support physicians and improve patient outcomes across the global medical device market. The target company was founded in 2017 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D., and has been backed by notable global investors such as BioStar Capital and Cue Growth Partners. The announcement is accompanied by a standard corporate introduction highlighting Stryker's leadership in MedSurg, Neurotechnology, and Orthopaedics, noting its impact on over 150 million patients annually. Contact information for investor relations and communications officers Nick Mead and Kim Montagnino was provided at the Portage, Michigan headquarters. While the press release includes a standard footer indicating it was published by a news wire service rather than directly by Markets Insider or Business Insider, the core content regarding the acquisition is substantial and specific to the company's strategic growth plans.